Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03721172 · ClinicalTrials.gov registry record · Phase 3
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT03721172 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 595 participants.
The verdict
NCT03721172, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
Interventions
- OTHER Placebo
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-07-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03721172
The ClinicalTrials.gov registry entry for NCT03721172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03721172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03721172 about?
NCT03721172 is a clinical study titled "Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy". This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis. Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to re...
What is the current status of trial NCT03721172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2019-03-11. Estimated completion is 2020-07-24.
What interventions are being tested in trial NCT03721172?
The interventions under investigation include: Placebo (OTHER), Apremilast (DRUG).
Who is sponsoring clinical trial NCT03721172?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.